Sequencing HER2+ therapies in breast cancer: insights on ADCs, TKIs, chemo, & maintenance strategies

Erika Hamilton, MD, Sarah Cannon Research Institute, Nashville, TN, explores how clinicians can navigate sequencing decisions in HER2+ breast cancer with expanding options including antibody-drug conjugates (ADCs) like trastuzumab deruxtecan, tyrosine kinase inhibitors (TKIs) such as tucatinib, and chemotherapy-based regimens. Emerging data from PATINA (NCT02947685) and HER2CLIMB-05 (NCT05132582) highlight the growing role of maintenance strategies, while differences in patient populations across trials underscore the importance of clinical context. As new results like DESTINY-Breast09 (NCT04784715) evolve, maintenance therapy may become central regardless of first-line induction choice. This interview took place at the San Antonio Breast Cancer Symposium (SABCS) 2025 Meeting in San Antonio, TX. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.